ID   5637rGEMCI20
AC   CVCL_RR14
DR   cancercelllines; CVCL_RR14
DR   Wikidata; Q54603871
RX   PubMed=26055179;
WW   Provider; RCCL; -; https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Doubling time: 41.8 hours (PubMed=26055179).
CC   Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0126 ! 5637
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 15
//
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002; PMCID=PMC4487788;
RA   Vallo, Stefan
RA   Michaelis, Martin
RA   Rothweiler, Florian
RA   Bartsch, Georg
RA   Gust, Kilian M.
RA   Limbart, Dominik M.
RA   Rodel, Franz
RA   Wezel, Felix
RA   Haferkamp, Axel
RA   Cinatl, Jindrich Jr.
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
//